alpha-1-B glycoproteinGenealiases: A1B · ABG · GAB · HYST2477
Q-omics provides the consensus-scored A1BG profile across patient tissues and cancer cell-line models. A1BG expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, A1BG is differentially expressed in 12, with the highest sampling consensus in LIHC. Additionally, A1BG protein abundance shows 27,755 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, LIHC, and LSCC as cancer lineages where A1BG shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for A1BG — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes A1BG survival associations across molecular data types. A1BG RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible A1BG RNA expression–survival associations across cancer types. High A1BG expression shows unfavorable associations in KIRC, MESO and LGG, but favorable associations in LUAD, LIHC and UVM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for A1BG RNA expression.
This table summarizes A1BG tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 7. The strongest signals are observed in LIHC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for A1BG. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. A1BG shows lower tumor expression in LIHC, CHOL and COAD and higher tumor expression in HNSC, THCA and BRCA. The LIHC box plot shows higher A1BG RNA expression in normal versus tumor tissue (log2 FC = −1.945, t-test p < 0.001).
This table shows molecular features associated with A1BG in patient tissues and cancer cell lines. In patient samples, A1BG shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, A1BG RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and BLOOD_Leukemia.
